Bortezomib is a proteasome inhibitor.
This drug targets heat-shock proteins associated with various neoplastic and inflammatory conditions and has been used for the treatment of plasmacytoma and other lymphoma variants such as Waldenström's macroglobulinemia.
Recommended dose in dogs is 0.0875 mg/kg given as an intravenous injection on days 1, 4, 8 and 11 of a 21-day cycle for a maximum of eight cycles.
- Huang S et al (2008) Proteasome inhibition 1 h following ischemia protects GRK2 and prevents malignant ventricular tachyarrhythmias and SCD in a model of myocardial infarction. Am J Physiol Heart Circ Physiol 294(3):H1298-H1303